Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, … Continue reading Biotech Volatile Stocks: Ultragenyx Pharmaceutical (NASDAQ:RARE), Sorrento Therapeutics (NASDAQ:SRNE), Five Prime Therapeutics (NASDAQ:FPRX), Aratana Therapeutics (NASDAQ:PETX), Pain Therapeutics (NASDAQ:PTIE)